A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers

Trial Profile

A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Fosbretabulin (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 20 Jan 2017 Primary endpoint Biomarker levels (Change from one or more baseline biomarker values for each patient to each study visit and study end [ Time Frame: 4 months ]) has not been met, according to Mateon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top